Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Mast Therapeutics, Inc. (MSTX) ended last trading session with a change of -2.9 percent. It trades at an average volume of 7.43M shares versus 3.1M shares recorded at the end of last trading session. The share price of $0.11 is at a distance of 57.86 percent from its 52-week low and down -84.44 percent versus its peak. The company has a market cap of $27.63M and currently has 250M shares outstanding. The share price is currently -10.4 percent versus its SMA20, -12.53 percent versus its SMA50, and -54.36 percent versus its SMA200. The stock has a weekly performance of -7.14 percent and is 22.78 percent year-to-date as of the recent close.

On March 6, 2017 Mast Therapeutics, Inc. (MSTX) reported financial results for the fourth quarter and year ended December 31, 2016.

“We are pleased with the progress made with AIR001 during the year and anticipate the closing of the merger with Savara to take place in the second quarter of this year,” stated Brian M. Culley, Chief Executive Officer.  “We believe this merger offers our stockholders a diversified, late-stage product development pipeline with important forthcoming milestones.”

Novavax, Inc. (NVAX) recently recorded -1.37 percent change and currently at $1.44 is 24.14 percent away from its 52-week low and down -83.04 percent versus its peak. It has a past 5-day performance of -2.04 percent and trades at an average volume of 6.4M shares. The stock has a 1-month performance of 9.09 percent and is 14.29 percent year-to-date as of the recent close. There were about 271.92M shares outstanding which made its market cap $391.56M. The share price is currently -1.57 percent versus its SMA20, 3.67 percent versus its SMA50, and -61.07 percent versus its SMA200.

On Feb. 27, 2017 Novavax, Inc., (NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016.

Novavax reported a net loss of $57.1 million, or $0.21 per share, for the fourth quarter of 2016, compared to a net loss of $78.8 million, or $0.29 per share, for the fourth quarter of 2015. For the twelve months ended December 31, 2016, the net loss was $280.0 million, or $1.03 per share, compared to a net loss of $156.9 million, or $0.60 per share, for the same period in 2015.